Back to dashboard
Low impact

Ibritumomab Tiuxetan (Zevalin) (CPB 0659, reviewed 2025-11-26)

Aetna·Medical Policy
Effective date
Not stated
We identified it
Aug 15, 2026
Days to comply
—

Related policy hubs